Press release
Cataplexy Pipeline Analysis, 2025 by DelveInsight | Avadel, Axome Therapeutics
Cataplexy Pipeline Analysis
According to DelveInsight, over three key companies are actively advancing more than three therapies for the treatment of cataplexy.
DelveInsight's "Cataplexy - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in cataplexy. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.
Request for a detailed cataplexy pipeline analysis report @ https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the cataplexy Pipeline Report:
*
DelveInsight's analysis of the cataplexy pipeline reveals a dynamic landscape, with more than three active companies developing over three investigational therapies across different stages of clinical development.
*
In December 2024, the FDA granted de novo classification and market authorization to ONWARD Medical's ARC-EX system. This non-invasive spinal cord stimulation device is the first approved to enhance hand strength and sensation in individuals with chronic cataplexy, with clinical trials showing that 72% of participants experienced improved hand function and sensory perception.
*
Earlier, in May 2024, the FDA approved Abbott's suite of Spinal Cord Stimulation (SCS) systems, including Prodigy, Proclaim Plus, Proclaim XR, and Eterna. These implantable neurostimulators are designed to alleviate chronic pain in the torso, arms, and legs, providing relief for patients with intractable pain conditions.
*
Leading companies such as Avadel, Axome Therapeutics, and others are actively evaluating new therapies to expand treatment options for cataplexy. Notable pipeline candidates in various stages of development include FT218, AXS12, among others.
Cataplexy Overview
Cataplexy is characterized by brief episodes of muscle weakness triggered by strong emotions, particularly positive ones such as laughter or excitement. These sudden attacks, lasting from a few seconds to several minutes, involve partial or complete paralysis of voluntary muscles, while muscles controlling eye movement and breathing remain functional. The condition is associated with the inhibition of serotonergic and noradrenergic neural pathways, which underlies the temporary muscle paralysis seen during cataplectic episodes.
Uncover the latest breakthroughs in cataplexy therapeutics, download our report @ https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cataplexy Pipeline Analysis
The cataplexy pipeline insights report 2025 provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the cataplexy Market.
*
Categorizes cataplexy therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging cataplexy drugs under development based on:
*
Stage of development
*
cataplexy Route of Administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
cataplexy Mechanism of Action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
cataplexy Licensing Agreements
*
Funding and investment activities that support future advancements in the cataplexy market.
Get Full Insights into the cataplexy Pipeline and Future Market Trends - Download the Report Now: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cataplexy Emerging Drugs
*
FT218: Avadel
FT218 is a GABA B receptor agonist originally developed by Flamel Technologies and is now being advanced by Avadel in Phase 3 clinical trials. The study, which started in June 2020 and is expected to finish by June 2022, enrolls around 250 participants (ClinicalTrials.gov ID: NCT04451668).
*
AXS12: Axome Therapeutics
AXS12 (Reboxetine) is a Phase 2 investigational therapy from Axsome Therapeutics for the treatment of cataplexy, acting as an adrenergic reuptake inhibitor.
Currently, around three key companies are actively developing cataplexy therapies, with Avadel leading the field with candidates in the most advanced stage (Phase III).
Cataplexy Pipeline Therapeutic Assessment
Cataplexy Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Cataplexy By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Cataplexy Assessment by Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Cataplexy Assessment by Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
Download the cataplexy Sample Report for Key Insights on the cataplexy Treatment Market and Therapeutics: https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Cataplexy Current Treatment Patterns
4. Cataplexy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cataplexy Late-Stage Products (Phase-III)
7. Cataplexy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cataplexy Discontinued Products
13. Cataplexy Product Profiles
14. Cataplexy Key Companies
15. Cataplexy Key Products
16. Dormant and Discontinued Products
17. Cataplexy Unmet Needs
18. Cataplexy Future Perspectives
19. Cataplexy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the cataplexy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cataplexy-pipeline-analysis-2025-by-delveinsight-avadel-axome-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cataplexy Pipeline Analysis, 2025 by DelveInsight | Avadel, Axome Therapeutics here
News-ID: 4170789 • Views: …
More Releases from ABNewswire
Andrew Leigh Honors Women Who Changed the Course Of History In Conversations Wit …
Andrew Leigh, co-founder of Maynard Leigh Associates, a leading UK training provider and much-published business author, has made a striking literary debut with his first non-fiction and non-business book, Conversations with Remarkable Women .
The book comprises imaginary conversations with twenty distinguished and high-achieving women from history. Leigh offers readers a fresh perspective on the lives and legacies of figures such as Catherine the Great, Mary Wollstonecraft, Harriet Tubman, Coco Chanel,…
McKay Law Continues Legacy of Excellence in East Texas Truck Accident Representa …
Record-Breaking Results Speak powerfully for clients
EAST TEXAS - October 27, 2025 - McKay Law, one of East Texas's most respected personal injury law firms, today reaffirmed its position as the region's premier choice for truck accident victims seeking maximum compensation and dedicated legal representation. With a proven track record of multi-million dollar verdicts, rapid-response investigation protocols, and an unwavering commitment to client success, McKay Law continues to set the standard…
Zero-Friction Automation: Anno Robot Offers 'Lifetime System Maintenance' and 90 …
The global retail sector is undergoing its most profound transformation in decades, driven by a confluence of rising labor costs, persistent staffing shortages, and a consumer demand for instant, 24/7 service. In this rapidly evolving landscape, the future of commerce is increasingly defined by automation. At the forefront of this shift is Anno Robot, a Shenzhen-based National High-Tech Enterprise that is not just selling robotic equipment but engineering a 'zero-friction'…
Client from Burkina Faso visited the company for an inspection, jointly embarkin …
During the inspection, accompanied by the heads of the company's foreign trade department and technology department, the client successively visited our company's production factory, product exhibition center and R&D laboratory. In the production workshop, the customer closely observed the automated production process of WPC wall panels [https://www.haofabm.com/wpc-interior-wall-panels-are-waterproof-scratch-resistant-environmentally-friendly-formaldehyde-free-and-feature-multi-color-textures-product/] and PU insulation wall panels [https://www.haofabm.com/pu-insulation-wall-panels-one-board-solves-insulation-and-weather-resistance-reducing-building-energy-consumption-by-30-directly-product/], and inquired in detail about the raw material selection standards, production process control points and quality inspection…
More Releases for Cataplexy
Cataplexy Market Comprehensive Analysis: Significant Growth Expected Across 7MM …
DelveInsight's comprehensive cataplexy market analysis reveals significant growth potential through 2034, driven by rising prevalence, technological advancements, and promising pipeline therapies. With limited current treatment options and unmet medical needs, the market presents substantial opportunities for pharmaceutical companies developing innovative cataplexy-specific therapies across the 7MM.
Key Findings
*
Market size projection: As per DelveInsight's analysis, the total market size of cataplexy in the 7MM is expected to change significantly during the forecast period…
Cataplexy Pipeline Insight, 2025: Advancing Therapeutics for a Complex Neurologi …
Cataplexy, a sudden and transient loss of muscle tone often triggered by strong emotions, is a debilitating symptom commonly associated with narcolepsy type 1. Current treatments primarily focus on symptom management, but significant unmet needs remain for therapies that offer improved efficacy, safety, and quality of life.
DelveInsight's "Cataplexy - Pipeline Insight, 2025" provides an in-depth analysis of the evolving therapeutic landscape for this rare neurological condition. The pipeline features innovative…
Cataplexy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight …
The cataplexy pipeline constitutes 3+ key companies continuously working towards developing 3+ cataplexy treatment therapies, according to DelveInsight.
DelveInsight's "Cataplexy - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in cataplexy. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.
Request for a detailed cataplexy…
Global Non Cataplexy Narcolepsy Drugs Market Analysis By Major Manufacturers and …
Non Cataplexy Narcolepsy Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Non Cataplexy Narcolepsy Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Children (Under 18) and Adult (18 to 50) are the major drivers for the industry.
Global Non…
Cataplexy Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Cataplexy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Cataplexy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cataplexy market size from 2019 to 2032, segmented…
Cataplexy Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Cataplexy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Cataplexy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cataplexy market size from 2019 to 2032, segmented…
